Technology Overview
Stem cell research is moving from the lab bench to the clinic. Induced pluripotent stem cells (iPSCs), gene editing and engineered immune cells now feed drug discovery, disease modeling and a growing pipeline of cell therapies. The field reaches from basic biology to regulatory filings, manufacturing scale-up and commercial products. For anyone tracking regenerative medicine, the pace and breadth of activity are hard to ignore.
This ebook covers that full landscape. Leading academic medical centers and research institutes such as Stanford, Salk, Kyoto's CiRA and WEHI drive discovery. Tool and reagent suppliers including STEMCELL Technologies, REPROCELL and Axol Bioscience supply the cells, media and platforms behind that work. Clinical-stage developers advance therapies for Duchenne muscular dystrophy, type 1 diabetes and nerve injury. The ebook also includes funders, professional societies, cord blood banks, regenerative clinics and contract manufacturers. Together they span oncology, neurology, cardiology, ophthalmology, aging and veterinary medicine.
Current Products and News
- Axogen, Inc. completed its acquisition of BioCircuit Technologies on October 1, 2026. The deal adds NerveTape™, described as the first FDA-cleared device for sutureless peripheral nerve repair. It follows the pricing of a $208.7 million public offering of common stock.
- The Cleveland Clinic reported that its first-in-human CRISPR-Cas9 gene-editing trial safely lowered LDL cholesterol by 52.5% and triglycerides by 47.8% at 12 months. The clinic also opened two new research buildings in the Cleveland Innovation District.
- Capricor Therapeutics is advancing its deramiocel BLA for Duchenne muscular dystrophy:
- An FDA advisory committee met in July 2026.
- The FDA extended the PDUFA target action date.
- HOPE-3 data appeared in The Lancet.
- Atara Biotherapeutics, Inc. resubmitted its Biologics License Application for tabelecleucel to the FDA on September 30, 2026.
- Seraxis, Inc signed a definitive merger agreement with Sernova on September 10, 2026, aiming to create a differentiated type 1 diabetes biotech company.
- International Society for Stem Cell Research (ISSCR) launched a new CDMO Directory to help researchers find manufacturing partners for clinical translation. It becomes available to nearly 5,000 members from October 19.
- STEMCELL Technologies formed a collaboration with Molecular Devices to speed adoption of organoid models through automation. It also partnered with CCRM to expand access to matched GMP and RUO iPSC lines for cell therapy development.
- Broad Stem Cell Research Center reported that UCLA scientists won CIRM grants to advance stem cell-based treatments for vision loss and infertility and to improve CAR T-cell therapy.
10 Leading Companies
- Stanford Medicine: A top-ranked academic medical center whose steady stream of research news includes ARPA-H contracts and PANORAMIC, a new open-source tool for decoding cell organization in tumors.
- Salk Institute for Biological Studies: A globally recognized life sciences institute producing major research, including a first body-wide single-cell atlas mapping DNA folding and epigenetics together.
- Memorial Sloan-Kettering Cancer Institute (MSK): A globally renowned oncology leader whose care and research include bone marrow transplantation and immunotherapy.
- Walter and Eliza Hall Inst of Medicine: An Australian institute with stem cell and regenerative medicine research, recently backed by $18.8 million in government funding for brain cancer drug development.
- Center iPS Cell Research and Application: Kyoto University's dedicated iPSC institute, spanning disease modeling, cell-based therapies and drug screening with pharmaceutical and biotech partners.
- Helmholtz Zentrum Munchen, GmbH: A major German research center with stem cell and bioengineering programs that just released ArchMap, a free single-cell analysis platform.
- The Cleveland Clinic: A world-ranked medical center showing clinical momentum, including its first-in-human CRISPR-Cas9 gene-editing trial results.
- Axogen, Inc.: A publicly traded regenerative medicine company expanding its nerve repair portfolio through the BioCircuit acquisition, backed by fresh capital.
- Axol Bioscience Ltd.: A leading iPSC provider with a busy 2026 that includes a capital raise, an acquisition, new partnerships and new ALS co-culture models.
- REPROCELL Inc: A global iPSC and cell technology provider advancing its StemEdit platform and StemRNA™ Clinical iPSC Seed Clones for GMP-ready cell therapy.
Get Ahead in Stem Cell Research
This market moves every day. On October 2, 2026 alone, 65 companies in this ebook updated their newsrooms. Computer Review puts all 349 companies across 33 countries in one place, with 200 job pages tracked, so you see the moves as they happen.
With a subscription you can:
- Catch every press release the day it is published
- Know who leads each company and who is hiring
- Size up markets country by country
- Find any company or topic in seconds with keyword search
Start today for just $15 a month, cancel any time, or get the best value at $120 a year and save 33%.
